Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Candiolo – page 9

187 clinical trials in Candiolo, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Candiolo at a glance
187
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

187 trials in Candiolo

Open in trial search

Malignant melanoma stage IV+1

Not recruiting

Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:BioNTech SE

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Non-small cell lung cancer metastatic

Not recruiting

Study comparing valemetostat tosylate plus pembrolizumab versus pembrolizumab alone in patients with advanced non-small cell lung cancer with high PD-L1 expression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Daiichi Sankyo Inc.

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing Acasunlimab and Pembrolizumab with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acasunlimab
  • Sponsor:Genmab A/S

Breast cancer

Not recruiting

Study on Chemotherapy and Aromatase Inhibitors (Exemestane, Letrozole, Anastrozole) for Post-Menopausal Patients with Early Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:IRCCS Ospedale Policlinico San Martino

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Plasma cell myeloma

Not recruiting

Study on Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Universita' Degli Studi Di Torino

Soft tissue sarcoma+1

Not recruiting

Study on Sunitinib and Nivolumab with Chemotherapy for Patients with Advanced Soft Tissue and Bone Sarcomas

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Asoc Grupo Espanol De Investigacion En Sarcomas

Non-small cell lung cancer metastatic

Not recruiting

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immutep

Follicular lymphoma

Not recruiting

Study on Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma Not Eligible for Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Fondazione Italiana Linfomi Ets

Follicular lymphoma

Not recruiting

Study Comparing Shortened vs Standard Chemotherapy with Rituximab for Initial Treatment of High Tumor Burden Follicular Lymphoma in Newly Diagnosed Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Fondazione Italiana Linfomi Ets

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Candiolo

What the registry says about research in the country

01 Hematologic Malignancies

Advanced research focusing on blood cancers including innovative treatments for myelodysplastic syndromes, follicular lymphoma, and chronic myelomonocytic leukemia. Studies evaluate novel drug combinations and maintenance therapies to improve patient outcomes.

  • Multiple Myeloma Treatment Optimization
  • Lymphoma Therapy Innovations
  • Leukemia Treatment Strategies

Trials investigate targeted therapies and immunotherapy approaches for better disease management.

02 Solid Tumors

Comprehensive research on lung cancer, breast cancer, and colorectal cancer. Studies explore combination therapies involving immunotherapy, targeted agents, and conventional treatments to enhance treatment efficacy.

  • Advanced NSCLC Treatments
  • Metastatic Disease Management
  • Novel Drug Combinations

Focus on personalized medicine approaches and biomarker-driven treatment selection.

03 Rare Cancers

Dedicated research into sarcomas, head and neck cancers, and other rare malignancies. Studies evaluate novel therapeutic approaches including immunotherapy combinations and targeted treatments.

  • Osteosarcoma Treatments
  • Soft Tissue Sarcoma Therapy
  • Innovative Treatment Protocols

Emphasis on developing effective treatments for cancers with limited therapeutic options.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.